A single stretch of chromosome 9 — the 9p21.3 locus — is the most consistently replicated region in genome-wide association studies for age-related disease. Coronary artery disease, type 2 diabetes, glioma, melanoma, and now physical aging have all been linked to variation here. At the heart of the locus sits ANRIL (antisense non-coding RNA in the INK4 locus)¹¹ ANRIL (antisense non-coding RNA in the INK4 locus)
Also designated CDKN2BAS or CDKN2B-AS1 — a long non-coding RNA transcribed antisense to the CDKN2A/CDKN2B tumor suppressor genes, a molecular rheostat for cellular senescence.

rs2811712 is a tag SNP within ANRIL that was identified in a landmark study as associated with physical function in older people²² associated with physical function in older people
Melzer D et al. A common variant of the p16INK4a genetic region is associated with physical function in older people. Mech Ageing Dev. 2007. The G allele — carried by roughly one in five people of European ancestry — is associated with substantially better preserved physical function in old age, while the common A allele is the risk-conferring genotype.

The Mechanism

The 9p21.3 locus contains three protein-coding genes — CDKN2A (encoding p16INK4a and p14ARF), CDKN2B (encoding p15INK4b), and MTAP — all flanked and overlapped by ANRIL. p16INK4a and p15INK4b are cyclin-dependent kinase inhibitors³³ cyclin-dependent kinase inhibitors
CDK inhibitors block CDK4/6, preventing phosphorylation of Rb and halting cell-cycle progression from G1 to S phase — the canonical senescence checkpoint that drive cellular senescence: as cells age and accumulate damage, p16 levels rise, arresting the cell cycle and converting cells into senescent "zombie" cells⁴⁴ senescent "zombie" cells
Senescent cells stop dividing but remain metabolically active, secreting pro-inflammatory cytokines (the SASP — senescence-associated secretory phenotype) that damage neighboring tissue that fuel the chronic inflammation underlying age-related functional decline.

ANRIL regulates CDKN2A/CDKN2B expression in cis through Polycomb group protein recruitment, particularly the PRC2 complex, which methylates histone H3K27 to silence the INK4 locus. In proliferating cells, ANRIL keeps senescence genes suppressed; as ANRIL expression shifts with aging or genetic variation, the balance tips toward elevated p16 and p15, accelerating the senescent phenotype. rs2811712 is an eQTL for CDKN2B expression: studies show that variation here correlates with altered ANRIL isoform abundance and downstream CDKN2B levels, providing a molecular pathway from genotype to functional aging phenotype.

The Evidence

The primary association was established by Melzer et al. (2007)⁵⁵ Melzer et al. (2007)
A common variant of the p16INK4a genetic region is associated with physical function in older people. Mechanisms of Ageing and Development. across three independent European cohorts totaling 3,372 elderly individuals (EPIC-Norfolk sets 1 and 2 plus InCHIANTI). Severely limited physical function — defined by performance-based tests of walking speed, chair stand, and balance — was present in 15.0% of AA homozygotes versus 7.0% of GG homozygotes, nearly half the rate. The per-A-allele odds ratio was 1.48 (95% CI 1.17–1.88, p = 0.001), adjusted for age, sex, and study. The association held across all three cohorts tested independently, including a trend in the Iowa-EPESE cohort (n=419, p=0.079 one-sided), making this one of the first robust genetic associations for functional aging specifically.

A Han Chinese case-control study Wu et al. (2012)⁶⁶ Wu et al. (2012)
Heterozygote genotypes at rs2222823 and rs2811712 SNP loci are associated with cerebral small vessel disease in Han Chinese population found the heterozygote genotype at rs2811712 was associated with OR 1.75 (CI 1.13–2.71, p=0.004) for cerebral small vessel disease — consistent with the broader pattern that the A (risk) allele at this locus impairs vascular and neurological aging beyond musculoskeletal function.

The broader 9p21.3 locus literature confirms that ANRIL variants influence CDKN2B expression and cellular senescence⁷⁷ CDKN2B expression and cellular senescence
SNPs here show inverse effects on ANRIL and CDKN2B expression, supporting a role of antisense transcription in regulating senescence pathways, with the risk alleles generally increasing ANRIL expression in ways that paradoxically reduce appropriate p16/p15 upregulation in vascular cells, impairing the normal senescence response to damage. This locus is the strongest genetic signal for coronary artery disease in Europeans (OR ~1.3 per risk allele), though rs2811712 itself does not independently associate with CAD — its primary documented phenotype is functional physical aging.

Practical Actions

For carriers of two A alleles (AA), the evidence supports a targeted approach to slowing the accumulation of senescent cells and their inflammatory secretome. The most directly relevant interventions for the CDKN2B/p16 axis include:

• Senolytic compounds: Fisetin (a flavonoid concentrated in strawberries and onions) and quercetin have demonstrated senolytic activity in human studies — selectively promoting apoptosis in p16-expressing senescent cells. Intermittent high-dose fisetin (≥500 mg/day for 2–3 days per month) reduced senescent cell burden and SASP markers in published clinical data.
• Cardiovascular monitoring: The 9p21.3 region is the strongest common genetic locus for coronary artery disease. While rs2811712 itself does not independently associate with CAD, it tags a haplotype block where other risk variants reside. AA carriers should ensure thorough cardiovascular risk assessment.
• Strength and resistance training: p16-driven muscle senescence contributes directly to sarcopenia (age-related muscle loss) — the leading mediator of physical impairment in older adults. Resistance training specifically reduces senescent cell burden in skeletal muscle and preserves muscle fiber function through mechanisms that parallel the CDKN2B pathway.

AG carriers carry one protective G allele: physical function risk is intermediate, and the same principles apply with moderated urgency.

Interactions

rs10757278 and rs1333049 (9p21.3 haplotype): These are the primary CAD-associated SNPs at the 9p21 locus, in moderate-to-high LD with rs2811712. If you carry the risk haplotype at rs10757278 (G allele) in addition to AA at rs2811712, the combined burden on ANRIL/CDKN2B regulation is likely greater than either marker alone. The 9p21.3 block spans ~58 kb and multiple SNPs contribute to its overall phenotypic effect.

rs564398 (upstream of CDKN2A): Another 9p21 tag SNP associated with type 2 diabetes and glioma risk, which shares the ANRIL regulatory context. Combined risk at rs2811712 and rs564398 may implicate broader ANRIL dysregulation beyond the physical aging phenotype.

Insulin-like growth factor 1 (IGF-1) is one of the most powerful anabolic hormones in the human body. It activates the PI3K/Akt/mTOR pathway¹¹ activates the PI3K/Akt/mTOR pathway
The canonical growth signaling cascade that controls muscle protein synthesis and hypertrophy, stimulates satellite cell activation²² satellite cell activation
Muscle stem cells that divide and fuse to repair damage and create new muscle tissue, and drives skeletal muscle hypertrophy in response to training. The rs35767 polymorphism sits in the promoter region of the IGF1 gene, 1,245 base pairs upstream of the transcription start site, where it regulates how much IGF-1 your body produces.

The A allele is associated with higher circulating IGF-1 levels compared to the C allele, and AA carriers tend to have greater muscle mass and superior athletic performance³³ greater muscle mass and superior athletic performance
Particularly in power and combined power-endurance sports like decathlon. This variant has emerged as one of the most replicated genetic markers for elite athletic performance.

The Mechanism

rs35767 is a regulatory variant located in the promoter region of the IGF1 gene on chromosome 12. The T-to-C substitution at position -1245 affects transcription factor binding and gene expression. Studies show the A allele leads to higher IGF-1 production, though the exact transcription factor interactions remain under investigation. Some research suggests the G allele may allow binding of C/EBPD transcription activator⁴⁴ G allele may allow binding of C/EBPD transcription activator
A DNA-binding protein that regulates gene expression, while other evidence indicates the A allele results in higher circulating levels through mechanisms that may involve altered promoter activity.

Once IGF-1 is secreted (primarily by the liver in response to growth hormone), it binds to IGF-1 receptors on muscle cells. This triggers a signaling cascade: PI3K converts PIP2 to PIP3, activating PDK1 and Akt. Akt then phosphorylates mTORC1, which activates ribosomal protein S6 and translation initiation factor eIF4E, ramping up protein synthesis. Simultaneously, Akt inhibits FoxO transcription factors, blocking the expression of muscle atrophy genes⁵⁵ blocking the expression of muscle atrophy genes
E3 ubiquitin ligases like atrogin-1 and MuRF1 that tag muscle proteins for degradation.

IGF-1 also activates muscle satellite cells—the stem cells responsible for muscle repair and growth. After intense exercise or muscle damage, satellite cells proliferate and differentiate into new myonuclei, contributing approximately half of the muscle mass gained during hypertrophy⁶⁶ half of the muscle mass gained during hypertrophy
Based on studies using viral IGF-1 delivery in animal models.

The Evidence

The rs35767 variant has been studied extensively in athletic populations. In a 2013 Israeli study of 87 power athletes and 78 endurance athletes⁷⁷ 2013 Israeli study of 87 power athletes and 78 endurance athletes
Including international and Olympic-level competitors, the A allele was significantly more frequent in top-level power athletes compared to national-level athletes. Among the elite power cohort, 4.8% carried the TT genotype versus 0% in non-athletic controls—a striking overrepresentation.

A 2022 study of decathlon athletes⁸⁸ 2022 study of decathlon athletes
Decathlon demands both power and endurance across 10 events found the AA genotype was significantly more prevalent among decathletes compared to other athlete groups, and AA carriers demonstrated superior speed performance. These findings align with the physiological role of IGF-1 in fast-twitch muscle fiber development and force production.

A 2024 meta-analysis⁹⁹ 2024 meta-analysis
Pooling data across multiple cohorts to increase statistical power confirmed the A allele as a favorable genetic marker for both power and endurance athletic performance, supporting the variant's role across multiple training modalities.

At the molecular level, a 2014 study of European adults¹⁰¹⁰ 2014 study of European adults
n=569 in discovery cohort measured circulating IGF-1 and found that carriers of the GG genotype (equivalent to TT on the minus strand) had significantly higher IGF-1 levels (218 ng/ml) compared to AA carriers (190 ng/ml, p=0.007). The higher IGF-1 group also showed better insulin sensitivity, suggesting metabolic benefits beyond muscle growth.

However, not all effects are beneficial. A Japanese longitudinal cohort of 1,506 individuals¹¹¹¹ Japanese longitudinal cohort of 1,506 individuals
Followed for long-term health outcomes found that AA carriers experienced faster decline in renal function over time compared to GG carriers, suggesting chronically elevated IGF-1 may have tradeoffs for kidney health.

Practical Actions

If you carry one or two A alleles, you have a genetic advantage for building muscle and responding to strength training. To capitalize on this:

Prioritize resistance training. Your elevated IGF-1 levels mean you're biochemically primed for hypertrophy. Focus on progressive overload—gradually increasing weight, volume, or intensity over time. AA carriers may see faster strength gains and better recovery from high-volume training compared to CC carriers.

Consume adequate protein. IGF-1 activates mTOR, the master regulator of protein synthesis, but mTOR needs amino acid availability to function. Aim for 1.6-2.2 g/kg body weight daily, with post-workout protein intake¹²¹² post-workout protein intake
20-40g within 2 hours of training to maximize the anabolic window when IGF-1 signaling is elevated.

Optimize sleep and recovery. Growth hormone (the primary driver of hepatic IGF-1 production) peaks during deep sleep. AA carriers producing more IGF-1 may benefit even more from adequate sleep (7-9 hours) for muscle repair and satellite cell activation.

Consider monitoring kidney function if you're TT. While the athletic benefits are clear, the Japanese cohort data suggests potential long-term renal effects. If you're a TT carrier pursuing intense athletic training, periodic monitoring of eGFR and creatinine may be prudent, especially as you age or if you have other kidney risk factors.

Interactions

rs35767 interacts with other variants in the IGF axis. rs7136446¹³¹³ rs7136446
An intronic IGF1 variant has also been associated with athletic performance and may compound with rs35767 to influence IGF-1 levels and muscle phenotype. Similarly, rs972936¹⁴¹⁴ rs972936
Another IGF1 intronic variant affects IGF-1 expression and has been linked to neurological outcomes and muscle force production.

Beyond the IGF1 gene, interactions with the growth hormone receptor and myostatin pathway are likely. Carriers of both the IGF1 A allele and myostatin rare R allele¹⁵¹⁵ myostatin rare R allele
Loss-of-function variants in MSTN that reduce this muscle growth inhibitor show even greater muscle mass and performance, suggesting an additive or synergistic effect.

For power athletes, the combination of rs35767 TT and ACTN3 RR¹⁶¹⁶ ACTN3 RR
Alpha-actinin-3, the "gene for speed" may represent an elite genetic profile for explosive strength and sprint performance.

Desmosomes are the mechanical rivets that hold cardiac muscle cells together under the repetitive stress of every heartbeat. Desmoplakin (DSP) is the master scaffold of the desmosome — the only structural protein that spans from the desmosome's cytoplasmic plaque all the way to the intermediate filaments inside the cell. When desmoplakin is compromised, desmosomal integrity fails under mechanical load¹¹ desmosomal integrity fails under mechanical load
DSP is the primary force transducer between the desmosome and the cytoskeleton, triggering a cascade of cellular detachment, fibrosis, and arrhythmia-prone scar tissue. The p.Ser987Pro variant at rs397516929 replaces a serine with proline at position 987 in the protein — a conservative-to-rigid substitution that likely alters the local protein conformation and mechanical resilience of the desmoplakin rod domain.

The Mechanism

The serine-987-to-proline substitution sits within the central rod domain of desmoplakin, a region critical for dimerization and mechanical resistance²² dimerization and mechanical resistance
desmoplakin functions as an antiparallel homodimer linked through its rod domain. Proline is the most conformationally constrained amino acid; its introduction into an alpha-helical region typically breaks or kinks the helix. In the context of a structural protein under cyclical mechanical stress, even partial impairment of rod domain rigidity or dimerization efficiency could reduce the desmosome's ability to maintain intercellular adhesion during high-demand periods.

Heterozygous loss-of-function in DSP causes disease through haploinsufficiency — one damaged copy reduces total desmoplakin output below the threshold required for sustained mechanical integrity in cardiomyocytes. The result is cardiomyocyte detachment, fatty-fibrous replacement, and patchy subepicardial fibrosis³³ cardiomyocyte detachment, fatty-fibrous replacement, and patchy subepicardial fibrosis
the fibrosis precedes and is disproportionate to systolic dysfunction in DSP cardiomyopathy, creating an arrhythmia-prone substrate that can trigger ventricular tachycardia and sudden cardiac death — often while left ventricular ejection fraction (LVEF) is still preserved.

DSP cardiomyopathy has a distinct inflammatory dimension absent from most heritable cardiomyopathies: 14–22% of carriers experience acute "hot phase" episodes of chest pain, troponin elevation, and new late gadolinium enhancement⁴⁴ 14–22% of carriers experience acute "hot phase" episodes of chest pain, troponin elevation, and new late gadolinium enhancement
mimicking myocarditis or acute coronary syndrome but without obstructive coronary disease. These episodes accelerate fibrosis accumulation and substantially increase subsequent arrhythmia risk.

The Evidence

DSP cardiomyopathy has been characterized in detail only in the past six years, and the Ser987Pro specific variant (ClinVar VCV000044888) has a single ClinVar submission from Mass General Brigham (2009, no assertion criteria), based on two patients with arrhythmogenic right ventricular cardiomyopathy. The variant is essentially absent from gnomAD population databases — consistent with a high-penetrance pathogenic variant under strong negative selection.

The broader DSP cardiomyopathy literature, however, is now substantial. Smith et al. (Circulation 2020) studied 107 patients with pathogenic DSP variants⁵⁵ Smith et al. (Circulation 2020) studied 107 patients with pathogenic DSP variants
Desmoplakin cardiomyopathy is a fibrotic and inflammatory form distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation 141:1872–1884, 2020 and showed that left ventricular predominant disease occurred in 55% of DSP patients (versus 0% for PKP2 mutations), with subepicardial late gadolinium enhancement in 40% and normal LVEF preserved in 35% of imaging-positive patients — fibrosis preceding dysfunction.

Wang et al. (Europace 2022), following 91 DSP variant carriers for a median 4.3 years⁶⁶ Wang et al. (Europace 2022), following 91 DSP variant carriers for a median 4.3 years
Clinical characteristics and risk stratification of desmoplakin cardiomyopathy. Europace 24:268–277, 2022, found a sustained ventricular arrhythmia (VA) incidence of 5.9 per 100 person-years. Myocardial injury events — the "hot phase" episodes — strongly predicted both arrhythmia (HR not quantified in abstract) and heart failure (HR not quantified).

The largest cohort to date, Gasperetti et al. (Eur Heart J 2025), enrolled 800 patients from 26 institutions⁷⁷ Gasperetti et al. (Eur Heart J 2025), enrolled 800 patients from 26 institutions
Clinical features and outcomes in carriers of pathogenic desmoplakin variants. Eur Heart J 46:362–376, 2025. Over 3.7-year follow-up, 17.4% developed sustained VA (3.9%/year) and 9.0% required heart failure hospitalization (1.8%/year). Independent VA predictors included female sex (aHR 1.547), prior non-sustained VT (aHR 1.721), prior sustained VA (aHR 1.923), LVEF ≤50% (aHR 1.645), and myocardial injury episodes (HR 2.394). Critically, 32.5% of patients met no conventional diagnostic criteria for ARVC, DCM, or NDLVC — underscoring that standard phenotypic thresholds miss many DSP carriers.

Bariani et al. (Heart Rhythm 2022), 73 Italian DSP carriers⁸⁸ Bariani et al. (Heart Rhythm 2022), 73 Italian DSP carriers
Clinical profile and long-term follow-up of a cohort of patients with desmoplakin cardiomyopathy. Heart Rhythm 2022, found major ventricular arrhythmias in 29% overall, with males experiencing dramatically worse outcomes: 52% arrhythmia vs 24% in females (p=0.036), and 31% cardiac death in males vs 0% in females (p<0.001). Females showed preferential left ventricular involvement.

The DSP Risk Score (Carrick et al., Eur Heart J 2024)⁹⁹ DSP Risk Score (Carrick et al., Eur Heart J 2024)
A novel tool for arrhythmic risk stratification in desmoplakin gene variant carriers. Eur Heart J 45:2968, 2024 integrates five clinical parameters — female sex, non-sustained VT history, PVC burden, LVEF <50%, and moderate-to-severe RV dysfunction (HR 6.0) — into a validated risk model with c-statistic 0.782, stratifying patients into low (<5%), intermediate (5–20%), and high-risk (>20%) five-year arrhythmia categories.

Practical Actions

DSP cardiomyopathy is actionable precisely because it is heritable (autosomal dominant, each child of a carrier has 50% risk), penetrant but variable in timing, and progressive in proportion to cumulative fibrosis. Carriers who are identified before symptoms emerge have the greatest window for preventive monitoring.

Cardiac magnetic resonance imaging (CMR) is the cornerstone of evaluation — echocardiography misses subepicardial fibrosis detectable only as late gadolinium enhancement. Ambulatory ECG monitoring quantifies PVC burden, one of the five parameters in the validated DSP risk score. Competitive sports restriction is recommended for carriers with confirmed disease phenotype, as exercise-induced myocardial stress can trigger "hot phase" episodes and accelerate fibrosis. For those progressing to high VA burden or reduced LVEF, ICD consideration follows standard ESC/AHA heart failure guidelines — though the LVEF <35% threshold used in dilated cardiomyopathy is insensitive for DSP disease, where arrhythmia risk is elevated even with preserved ejection fraction.

First-degree relatives of confirmed carriers should undergo clinical and genetic evaluation. Cascade genetic testing identifies pre-symptomatic carriers before fibrosis has accumulated.

Interactions

DSP cardiomyopathy shares phenotypic overlap with PKP2 (plakophilin-2) and DSG2 (desmoglein-2) variants — all desmosomal genes whose proteins form the macromolecular complex at the intercalated disc. Compound heterozygosity or digenic combinations with PKP2 variants have been reported and may produce more severe phenotypes with earlier onset and biventricular involvement, though systematic data on specific genotype combinations are limited. SCN5A variants (sodium channel) have been found as potential modifiers of arrhythmia severity in some desmosomal cardiomyopathy families. Carriers with concurrent hypertension or obesity face accelerated fibrosis progression due to increased hemodynamic wall stress amplifying desmosomal vulnerability.

Your brain makes its own cholesterol — and unlike the rest of your body, it has almost no way to get rid of it. The blood-brain barrier blocks cholesterol from simply diffusing out, so the brain relies almost entirely on a single enzyme, cholesterol 24-hydroxylase¹¹ cholesterol 24-hydroxylase
encoded by CYP46A1, a cytochrome P450 enzyme expressed almost exclusively in neurons, to convert excess cholesterol into 24S-hydroxycholesterol (24S-OHC) — a metabolite that can cross the blood-brain barrier and exit the brain. This makes CYP46A1 the primary gatekeeper of brain cholesterol homeostasis and a direct regulator of how much cholesterol accumulates in neurons over time.

The Mechanism

rs4900442 sits in intron 3 of the CYP46A1 gene (the IVS3+43 C>T variant), placing it in a non-coding region that likely influences mRNA splicing efficiency or regulatory element binding rather than the amino acid sequence of the enzyme itself. The C allele, which is the reference allele and the globally more common variant (~55% frequency), appears to be associated with altered enzyme activity or expression — manifesting as a higher ratio of 24S-hydroxycholesterol to cholesterol in cerebrospinal fluid²² 24S-hydroxycholesterol to cholesterol in cerebrospinal fluid
CSF levels of 24S-OHC reflect the rate of CYP46A1-catalysed cholesterol turnover in the brain; an elevated ratio suggests dysregulated flux among CC homozygotes with Alzheimer's disease. Disrupted brain cholesterol turnover is mechanistically plausible as an Alzheimer's risk pathway: cholesterol accumulation in neuronal membranes can promote amyloid-beta production and tau phosphorylation, both core features of AD pathology.

The Evidence

The original association was reported by Kölsch et al. in 2002³³ Kölsch et al. in 2002
Kölsch H et al. Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Mol Psychiatry 2002;7:899–902 in a German cohort of 114 AD patients and 144 healthy controls. They found the C allele of the IVS3+43 C>T variant significantly more prevalent in AD patients, and additionally demonstrated that CC genotype carriers had an elevated 24S-OHC/cholesterol ratio in CSF — providing a direct biochemical link between genotype and brain cholesterol metabolism.

A 2016 meta-analysis by Jia et al.⁴⁴ 2016 meta-analysis by Jia et al.
Jia F et al. The association between CYP46A1 rs4900442 polymorphism and the risk of Alzheimer's disease: a meta-analysis. Neurosci Lett 2016;620:83–87 pooled six case-control studies covering 1,555 AD cases and 1,347 controls. The overall analysis found no statistically significant association (allele model OR=0.947), but a significant protective effect of the T allele emerged specifically in Chinese populations (OR=0.780, 95% CI 0.628–0.968), with no equivalent signal in Caucasian cohorts. This population-specific finding is consistent with the broader literature on CYP46A1 variants, where effect sizes and directions vary substantially across ancestries.

A related but distinct variant (rs754203, the intron 2 T/C polymorphism) has been more extensively studied and shows similarly mixed results in the largest meta-analysis to date — 21 studies, 4,875 AD cases, 4,874 controls — where the CC genotype of that neighboring variant confers modestly increased risk (recessive model OR=1.20) and the effect is amplified among APOE ε4 carriers⁵⁵ amplified among APOE ε4 carriers
Li L et al. CYP46A1 T/C polymorphism associated with the APOE ε4 allele increases the risk of AD. J Neurol 2013;260:1446–1455. The rs4900442 and rs754203 variants are in partial linkage disequilibrium and likely tag overlapping haplotypes within the CYP46A1 locus.

The overall evidence picture is moderate: the biological mechanism is well-established (CYP46A1 controls the dominant route of brain cholesterol elimination), the CSF biomarker data provide functional support, but the genetic association is population-specific and the effect size is modest.

Practical Actions

The actionable implication of impaired CYP46A1 function focuses on modifiable factors that can influence brain cholesterol homeostasis through parallel routes. The most important consideration is the well-documented interaction with APOE genotype: the risk associated with CYP46A1 C alleles appears substantially amplified in APOE ε4 carriers, making combined genotyping particularly informative.

Efavirenz⁶⁶ Efavirenz
an antiretroviral drug that acts as a low-dose CYP46A1 activator — repurposing studies are underway has been investigated at sub-therapeutic doses as a pharmacological activator of CYP46A1, and early research suggests it may restore normal brain cholesterol turnover. This is a research-stage observation and not a current clinical recommendation.

Statins do not readily cross the blood-brain barrier and do not directly substitute for CYP46A1 function in the brain; they act on peripheral cholesterol, leaving brain cholesterol metabolism largely untouched.

Interactions

The most clinically relevant interaction is with rs429358 (APOE ε4 determinant). Li et al. 2013 demonstrated that APOE ε4 carriers with the CC genotype at the related rs754203 locus (and by extension, likely at rs4900442) face significantly greater Alzheimer's disease risk than either risk factor alone would predict. CYP46A1 and APOE are both central to brain lipid metabolism, and their interaction is mechanistically coherent: impaired 24S-OHC production compounds with APOE ε4-driven amyloid accumulation.

The intron 2 variant rs754203 is the most extensively studied CYP46A1 polymorphism in Alzheimer's disease research. rs4900442 and rs754203 are in partial LD and likely tag the same underlying haplotype structure within the CYP46A1 locus. Their combined effect has not been formally modeled in published studies.

Toll-like receptor 4 (TLR4)¹¹ Toll-like receptor 4 (TLR4)
The primary innate immune receptor for lipopolysaccharide (LPS), a structural component of Gram-negative bacterial cell walls orchestrates your body's first response to bacterial threats. The Thr399Ile variant (rs4986791) — a C-to-T transition at coding position 1196 that replaces threonine with isoleucine at protein position 399²² replaces threonine with isoleucine at protein position 399
This occurs in the extracellular domain of TLR4 — is an important functional variant in its own right, yet one that has long lived in the shadow of its neighbor.

Unlike the Asp299Gly variant (rs4986790), Thr399Ile does not independently disrupt TLR4 signaling in isolated cell-culture experiments. But in living humans, these two variants almost always travel together on the same chromosome. They co-segregate on a single haplotype³³ They co-segregate on a single haplotype
Most carriers of Thr399Ile are also carriers of Asp299Gly, and vice versa. This tight genetic coupling means their combined effect on immune recognition — reduced LPS sensing, dampened cytokine production, altered neutrophil responses — is the relevant biology for nearly everyone carrying either variant. The T allele occurs at about 6.4% frequency in Europeans but is exceptionally rare in East Asians (0.04%); interestingly, South Asians and Finns show notably higher frequencies (~10.5% and ~12.2% respectively).

GWAS analyses provide an independent line of evidence: rs4986791 is among the strongest genetic determinants of TLR4:MD-2 protein complex levels in blood (MD-2 is the co-receptor that enables TLR4 to recognize LPS), with effect sizes reaching beta = −0.94 to −1.27 at p < 10⁻³⁴, indicating the T allele substantially reduces circulating TLR4/MD-2 complex abundance regardless of the co-occurring Asp299Gly variant.

The Mechanism

Thr399Ile sits in the extracellular domain of TLR4, in a region involved in forming the receptor complex with MD-2 and LPS. While functional studies using isolated Thr399Ile-only constructs found no independent disruption of LPS-induced NF-κB signaling, the variant reduces TLR4:MD-2 protein complex abundance at the cell surface. When combined with Asp299Gly on the same haplotype, neutrophils show reduced phosphorylation of IκB⁴⁴ reduced phosphorylation of IκB
IκB is the inhibitor of NF-κB; its reduced phosphorylation means NF-κB stays in its inactive state, blunting inflammatory gene transcription, diminished IL-6 and TNF-α production after LPS stimulation, and reduced suppression of apoptosis — the combination yielding a pronounced loss-of-function phenotype in real-world immune contexts.

The Evidence

The inflammatory bowel disease evidence is among the most replicated findings. A meta-analysis of 49 case-control studies found significant associations between rs4986791 and IBD risk⁵⁵ A meta-analysis of 49 case-control studies found significant associations between rs4986791 and IBD risk
Analysis included both Crohn's disease and ulcerative colitis. A separate meta-analysis confirmed significantly higher frequencies of Thr399Ile in patients with IBD, Crohn's disease, and ulcerative colitis⁶⁶ A separate meta-analysis confirmed significantly higher frequencies of Thr399Ile in patients with IBD, Crohn's disease, and ulcerative colitis
The 399Ile allele carriage was elevated in UC patients as well as CD patients in this analysis. These findings are biologically coherent: reduced TLR4 recognition of gut-resident bacteria is thought to impair mucosal immune homeostasis, allowing commensals to trigger aberrant inflammation.

For sepsis, the picture is clearer than for Asp299Gly. A meta-analysis of 17 studies encompassing 2,212 cases and 3,880 controls found an odds ratio of 1.16 (95% CI: 0.70–1.91, p = 0.57) for Thr399Ile and sepsis⁷⁷ A meta-analysis of 17 studies encompassing 2,212 cases and 3,880 controls found an odds ratio of 1.16 (95% CI: 0.70–1.91, p = 0.57) for Thr399Ile and sepsis
This non-significant result held across Caucasian populations. There is no meaningful independent association between this variant and sepsis susceptibility.

Emerging evidence links rs4986791 to cancer susceptibility. A meta-analysis of 87 case-control studies found the T allele associated with increased cancer risk (OR 0.74 for C vs T model)⁸⁸ A meta-analysis of 87 case-control studies found the T allele associated with increased cancer risk (OR 0.74 for C vs T model)
The study spanned prostate, lung, gastric, hepatocellular, and colorectal cancers, among others. A separate case-control study found rs4986791 variant genotypes associated with increased acute myeloid leukemia (AML) susceptibility, OR 1.61 (95% CI: 1.001–2.59) in the dominant model⁹⁹ rs4986791 variant genotypes associated with increased acute myeloid leukemia (AML) susceptibility, OR 1.61 (95% CI: 1.001–2.59) in the dominant model
The combined effect of rs4986790 + rs4986791 yielded OR 3.14 for AML development. For respiratory disease, a meta-analysis of 11 studies found significant asthma association especially among Asian populations¹⁰¹⁰ a meta-analysis of 11 studies found significant asthma association especially among Asian populations
One pediatric study found CT genotype children were more likely to develop severely persistent asthma.

Practical Implications

Because Thr399Ile almost always co-occurs with Asp299Gly, the practical actions for carriers mirror those for Asp299Gly carriers — vigilant infection prevention, attention to gastrointestinal symptoms, and awareness of IBD risk. The additional evidence here for asthma and cancer susceptibility adds nuance: the T allele appears to be a general marker of altered innate pattern recognition, with downstream consequences across multiple inflammatory and immune-surveillance pathways.

The significantly reduced TLR4:MD-2 complex levels in T allele carriers suggest a mechanistically grounded reason for the reduced immune surveillance: there are simply fewer functional receptor complexes available to detect bacterial signals at mucosal surfaces.

Interactions

Thr399Ile (rs4986791) and Asp299Gly (rs4986790) co-segregate on the same haplotype in virtually all carriers¹¹¹¹ co-segregate on the same haplotype in virtually all carriers
In population studies, essentially every Thr399Ile carrier also carries Asp299Gly. This means interpreting either variant in isolation is biologically incomplete. The compound haplotype shows more pronounced impairment of innate immune responses than either variant alone, including reduced neutrophil NF-κB activation and cytokine production. This interaction is the most important genetic context for rs4986791 — for most carriers, the functional picture is the same as for the compound double carrier. TLR4 co-receptor variants such as the CD14 -260 C>T polymorphism, which alters CD14 expression and LPS delivery to TLR4, may further modulate the effect of this haplotype on mucosal immunity and IBD risk.

Most people have heard of Factor V Leiden or prothrombin G20210A as genetic drivers of venous blood clots. TC2N (Tandem C2 Domains, Nuclear) barely appeared on coagulation researchers' radar until 2022 — yet genome-wide studies now place this gene at a locus with one of the most statistically significant associations with venous thromboembolism (VTE) identified to date. VTE¹¹ VTE
venous thromboembolism, encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE) is responsible for approximately 100,000–300,000 deaths per year in the United States alone. Understanding its genetic architecture helps identify people at elevated baseline risk who may benefit from more vigilant prevention strategies.

The Mechanism

TC2N encodes a 490-amino-acid protein containing two tandem C2 domains²² C2 domains
calcium- and lipid-binding structural motifs found in many signaling proteins, including synaptotagmins and protein kinase C (C2A spanning residues 223–342; C2B spanning residues 344–471). The protein carries a nuclear localization signal and is predicted to be active in the nucleus, with phosphorylation sites documented in platelet proteomics datasets — raising the possibility that TC2N participates in nuclear signaling cascades relevant to hemostatic cell function.

The rs57035593 variant sits deep within intron 5 of TC2N (c.469+502, 502 nucleotides from the exon boundary) on the minus strand of chromosome 14q32.12. As an intronic variant, it does not change the TC2N protein sequence. Instead, it almost certainly acts as a tag SNP³³ tag SNP
a variant in strong linkage disequilibrium with a nearby causal regulatory or coding variant that is harder to genotype directly or as a regulatory element affecting TC2N expression in relevant tissues. GTEx data show that this variant is an eQTL for the nearby CATSPERB gene in whole blood, suggesting complex local regulatory architecture in this chromosomal region.

The biological plausibility of TC2N in hemostasis was formally tested and confirmed: CRISPR/Cas9 knockdown of tc2n in zebrafish⁴⁴ CRISPR/Cas9 knockdown of tc2n in zebrafish
laser-mediated endothelial injury model; fish with tc2n knockdown showed significantly abnormal thrombus formation, demonstrating the gene is required for normal in vivo hemostasis produced a measurable hemostatic phenotype in the laser endothelial injury model, placing TC2N alongside well-validated coagulation genes. This makes TC2N one of only a handful of GWAS-nominated VTE loci to have direct experimental functional validation in an in vivo model.

The Evidence

The primary GWAS evidence comes from a landmark cross-ancestry meta-analysis by Thibord et al.⁵⁵ cross-ancestry meta-analysis by Thibord et al.
Circulation 2022, 81,669 VTE cases and controls across European, African, and Hispanic ancestries, 135 independent loci, GCST90797304 which identified rs57035593 at genome-wide significance (p = 3×10⁻³⁸, β = 0.071 per T allele). This effect size, while modest on an individual scale, is consistent with the polygenic architecture of VTE — cumulative risk from many loci adds up substantially.

Independent confirmation comes from Ghouse et al.⁶⁶ Ghouse et al.
Nature Genetics 2023, 81,190 VTE cases and 1,419,671 controls, 93 risk loci of which 62 were previously unreported and the subsequent Wolford et al. multipopulation GWAS⁷⁷ Wolford et al. multipopulation GWAS
Blood Advances 2025, 27,987 cases and 1,035,290 controls from 9 international cohorts, 38 genome-wide significant loci, which provided the zebrafish validation. Together these three large studies, spanning over 100,000 VTE cases globally, converge on TC2N as a genuine VTE susceptibility locus with both statistical and experimental support.

Practical Actions

TC2N rs57035593 is a common variant — roughly half of people globally carry at least one T allele. Like other polygenic VTE risk factors, it operates in the background of overall thrombotic risk, amplified by situational risk factors such as prolonged immobility, surgery, oral contraceptive use, pregnancy, cancer, or dehydration. People who carry two T alleles (about 8–11% of Europeans and East Asians) carry the highest baseline genetic risk from this particular locus.

Because anticoagulant therapy for primary VTE prevention has its own bleeding risks, genetic risk alone is not sufficient to justify prophylactic anticoagulation. The clinical value of knowing this genotype lies in heightened awareness during high-risk periods: long-haul travel, hospitalization, post-surgical recovery, and pregnancy. These are the windows where preventive measures — compression stockings, early mobilization, adequate hydration, and when clinically indicated, pharmacological prophylaxis — have strong evidence behind them.

Interactions

TC2N rs57035593 is one of over 90 validated VTE susceptibility loci. Its effect is additive with other known thrombophilic variants: Factor II prothrombin G20210A (rs1799963), Factor V Leiden (rs6025), and fibrinogen gamma-chain variants (rs2066865). Individuals who carry rs57035593-TT alongside any of these high-penetrance variants face compounded risk that approaches the level seen with monogenic thrombophilias. The Ghouse et al. polygenic risk score showed that individuals in the top 0.1% of cumulative genetic VTE risk have risk equivalent to homozygous F2/F5 variant carriers — a finding that underscores why the full polygenic context matters.

Oral contraceptives and hormone replacement therapy are the most clinically relevant environmental interactions: estrogen-containing preparations increase VTE risk 3–6-fold in the general population, and this effect is additive with genetic predisposition from multiple VTE loci including TC2N.

Most people know vitamin B12 deficiency from its classic blood tests — low serum B12, megaloblastic anemia. But the real question for cellular function is not how much B12 circulates in total, but how much reaches your cells. That depends almost entirely on one transport protein: transcobalamin II¹¹ transcobalamin II
The only B12-binding protein able to deliver cobalamin into cells via the CD320 receptor on cell surfaces; about 20–25% of circulating B12 is bound to this protein, forming "holotranscobalamin" (holoTC), the active fraction (TCN2). The rs5753231 variant sits approximately 2 kilobases upstream of the TCN2 gene — in the promoter-proximal region that governs how much transcobalamin II your liver and other tissues produce.

Unlike the well-studied TCN2 coding variant rs1801198 (Pro259Arg), which impairs the protein's ability to bind and release B12, rs5753231 affects a different level of regulation: the amount of TCN2 protein your body makes in the first place. The rare T allele is associated with higher circulating transcobalamin II levels — potentially translating to a modest advantage in B12 delivery capacity.

The Mechanism

rs5753231 falls in a 2KB upstream region²² 2KB upstream region
By convention, "2KB upstream" means within 2,000 base pairs of the gene's transcription start site — a region rich in regulatory elements including promoter sequences, enhancer-binding sites, and transcription factor recognition motifs of TCN2 on chromosome 22q12.2. Variants in this class of regulatory elements can alter gene expression by affecting transcription factor binding³³ transcription factor binding
Proteins that attach to specific DNA sequences upstream of a gene and control how frequently that gene is transcribed into mRNA, RNA stability, or promoter efficiency without changing the amino acid sequence of the resulting protein.

The T allele is associated with higher serum TCN2 protein — a pattern consistent with increased transcriptional activity at this locus. More TCN2 protein in circulation means a greater capacity to load and deliver cobalamin to peripheral tissues. The C allele (carried by most people) represents the population-average expression level.

Because this is a promoter-region variant rather than a missense change, its functional impact is probabilistic rather than structural: it shifts the average abundance of a fully functional protein rather than reducing that protein's per-molecule effectiveness.

The Evidence

Two independent large-scale protein GWAS have identified rs5753231-T as a cis-pQTL for serum TCN2 levels. The Sun et al. 2018 Genomic Atlas⁴⁴ Sun et al. 2018 Genomic Atlas
Sun BB et al. Genomic atlas of the human plasma proteome. Nature, 2018 — a landmark analysis of 1,478 plasma proteins in 3,301 healthy blood donors from the INTERVAL cohort — detected the rs5753231-T association with TCN2 protein at genome-wide significance (beta = 0.21, p = 8 × 10⁻¹³). This effect survived strict multiple-testing correction across the entire plasma proteome.

The Gudjonsson et al. 2022 serum protein GWAS⁵⁵ Gudjonsson et al. 2022 serum protein GWAS
Gudjonsson A et al. A genome-wide association study of serum proteins reveals shared loci with common diseases. Nature Communications, 2022 independently replicated the association in 5,368 participants from the AGES-Reykjavik cohort (beta = 0.117, p = 3 × 10⁻⁷), confirming that the effect is not cohort-specific.

Both studies detect TCN2 protein quantity (total transcobalamin II in circulation) rather than functional holotranscobalamin (B12-loaded TCN2). Higher total TCN2 theoretically increases the pool available to be loaded with cobalamin, but the downstream functional significance — whether T allele carriers have meaningfully better cellular B12 delivery — has not been directly tested in dietary or clinical intervention studies. This places the clinical relevance at an emerging evidence level⁶⁶ emerging evidence level
Single studies or pQTL associations without clinical outcomes data; the biological direction is clear but the practical effect size for individuals has not been quantified.

ClinVar classifies rs5753231-T as benign/likely-benign for transcobalamin II deficiency, consistent with its protective (rather than loss-of-function) direction.

Practical Actions

For TT homozygotes, the pQTL data suggests a modestly elevated baseline transcobalamin II pool. The most practical implication is that standard B12 monitoring is appropriate, and holotranscobalamin (holoTC) testing — which directly measures the active B12 fraction — would give the most relevant picture of actual transport capacity.

For CC homozygotes (the majority), this is a neutral finding at this evidence level; no corrective action is indicated. The actionable variants for TCN2 are the coding changes in rs1801198 and rs1131603, which directly alter the protein's B12-binding function.

Interactions

rs5753231 is an independent secondary association signal at the TCN2 locus, distinct from the coding variant rs1801198 (Pro259Arg). The two variants capture different aspects of TCN2 biology: rs1801198 affects protein function (B12-binding efficiency), while rs5753231 affects protein abundance (expression level). Individuals carrying the GG genotype at rs1801198 (reduced binding efficiency) alongside the CC genotype at rs5753231 (lower expression) represent a double hit on transcobalamin function — although direct interaction studies are lacking.

The broader one-carbon metabolism pathway context is the same as for rs1801198: adequate cellular B12 is needed for methionine synthase (MTR, rs1805087) to recycle homocysteine, and methionine synthase reductase (MTRR, rs1801394) to keep that enzyme active. TCN2 variants upstream or coding both feed into the same pathway limitation when B12 delivery to cells is suboptimal.

Von Willebrand factor is the scaffold protein of primary hemostasis: it bridges platelets to exposed collagen at a vascular injury site, and it ferries coagulation factor VIII through the bloodstream. To function, VWF must assemble into massive chain-like multimers¹¹ multimers
Ultra-large VWF multimers can span hundreds of individual VWF subunits and are far more effective at capturing platelets under the high shear stress of arterial blood flow than small multimers. rs61754011 disrupts that assembly at its very first step.

The Mechanism

The VWF gene encodes a precursor protein (pro-VWF) that begins with a large propeptide — the D1 and D2 domains — that acts as a chaperone. Inside the Golgi apparatus²² Golgi apparatus
The cellular organelle where VWF propeptides dimerize and then oligomerize into multimers before being packaged for secretion, the D2 domain orchestrates disulfide-linked end-to-end joining of VWF dimers into the high molecular weight (HMW) multimer chains that give VWF its clotting efficacy. The Gly550Arg substitution — a glycine replaced by the bulkier, charged arginine — disrupts this multimerization step. The resulting VWF is secreted but lacks its largest, most hemostatically active multimers.

This mechanism defines VWD type 2A: qualitative VWF deficiency with selective loss of HMW multimers and a VWF activity-to-antigen ratio below 0.7. Factor VIII levels are typically normal to mildly reduced. On electrophoretic multimer analysis, the large multimer bands are absent or greatly diminished.

The rs61754011 variant shows autosomal recessive inheritance³³ autosomal recessive inheritance
Heterozygous family members of the index case were phenotypically normal or only mildly affected; the full VWD type 2A phenotype required homozygosity. This recessive pattern distinguishes it from most VWD type 2A mutations, which are dominant — the Gly550Arg D2 domain defect impairs multimerization when present in both alleles, but a single wild-type allele produces sufficient functional propeptide to support normal multimer assembly.

The Evidence

The Gly550Arg mutation was first identified by Schneppenheim et al. in 1995⁴⁴ first identified by Schneppenheim et al. in 1995
In a German kindred, the proband was homozygous Gly550Arg with epistaxis, easy bruising, and menorrhagia; heterozygous relatives were phenotypically normal or borderline-abnormal. Laboratory findings in the homozygote included absent HMW multimers on electrophoresis and a reduced VWF ristocetin cofactor (VWF:RCo) activity disproportionate to VWF antigen level (VWF:Ag) — the hallmark ratio of type 2 VWD. The variant was originally classified as VWD type IIC (propeptide-defective multimerization) and was re-classified as VWD type 2A under the current Sadler 2006 nosology⁵⁵ Sadler 2006 nosology
The updated classification unified VWD subtypes IIA, IIC, IID, IIE, and related propeptide-defect types under the single "type 2A" umbrella.

Because the variant is exceedingly rare in population databases (not detected in gnomAD or the ALFA population dataset across >10,000 chromosomes), population-level frequency estimates are unavailable. The recessive inheritance means most carriers (CT genotype) are unknown to themselves and require clinical investigation only if they have a consanguineous pedigree or a homozygous affected family member. ClinVar classifies the Gly550Arg allele as Pathogenic (VCV000000305) for VWD type 2A based on functional and clinical evidence.

Practical Actions

For homozygous carriers (TT), the clinical picture is von Willebrand disease type 2A — a moderate qualitative bleeding disorder. The cardinal symptoms are mucocutaneous bleeds: frequent or prolonged nosebleeds, easy bruising, gum bleeds, and in women, heavy menstrual periods. Joint bleeds are uncommon.

Management of VWD type 2A focuses on two therapeutic tools: Desmopressin (DDAVP) releases stored VWF from endothelial Weibel-Palade bodies, transiently raising VWF levels 3–5-fold. In type 2A it may provide partial benefit for minor bleeds, but the released VWF still lacks HMW multimers (because the defect is in propeptide-mediated assembly, not in release), so response is typically incomplete. A desmopressin trial under clinical supervision is necessary before relying on it for procedural prophylaxis. VWF concentrate (plasma-derived, e.g. Humate-P, Wilate) delivers functional VWF with a full multimer distribution and is the definitive treatment for major bleeds, surgery, and procedures when desmopressin response is insufficient.

Heterozygous carriers (CT) are typically clinically normal, though mildly reduced VWF:RCo values may appear on sensitive laboratory testing. No treatment is usually indicated, but formal assessment before elective surgery or invasive procedures is prudent.

Interactions

Because this variant follows autosomal recessive inheritance, the clinical risk in heterozygous carriers becomes significant primarily in the context of consanguinity (two carrier parents produce a 25% probability of a homozygous child). ABO blood group (rs505922 / ABO locus) is a major modifier of VWF levels in everyone: blood group O individuals have ~25% lower VWF than non-O, which can compound mild VWF quantitative reductions. However, for the Gly550Arg defect — which is a qualitative structural problem, not a quantitative one — ABO modulation is a secondary consideration. Clinicians managing affected individuals should assess the full coagulation profile including FVIII activity, VWF:Ag, VWF:RCo, and multimer electrophoresis to characterise individual phenotype severity.

Paraoxonase-1 (PON1) is an enzyme that rides on HDL particles¹¹ HDL particles
High-density lipoprotein, often called "good cholesterol," transports cholesterol from tissues back to the liver in your bloodstream, where it performs two critical jobs: detoxifying organophosphate pesticides²² organophosphate pesticides
Compounds widely used in agriculture that can be neurotoxic; PON1 breaks down their active metabolites and protecting LDL cholesterol from oxidative damage³³ oxidative damage
Oxidized LDL is a key driver of atherosclerosis, the buildup of plaques in artery walls. The Q192R variant creates two functionally different versions of the enzyme with a striking tradeoff: the R variant is better at breaking down pesticides, while the Q variant is superior at preventing LDL oxidation and protecting against cardiovascular disease.

The Mechanism

The Q192R polymorphism results from an A>G nucleotide change that exchanges an arginine (R) for glutamine (Q) at position 192 of the protein . This amino acid substitution alters the enzyme's active site⁴⁴ active site
The region of an enzyme where substrates bind and chemical reactions occur, changing its catalytic efficiency for different substrates.

The Q isoform can reduce copper-mediated LDL oxidation by 58-61%, whereas the R genotype inhibits LDL oxidation by only 36-48% . However, the situation reverses for organophosphate metabolism— purified PON192 alloforms show the R variant has higher catalytic efficiency for hydrolysis of specific oxon substrates , making RR individuals better protected against pesticide poisoning but more vulnerable to cardiovascular disease.

The Evidence

The cardiovascular implications are substantial.

In a Saudi study of 2,456 individuals, the RR genotype was associated with CAD risk with an OR of 2.2 (95% CI 1.4-7.4, p < 0.01), independent of age, gender, smoking, obesity, and diabetes .

In Chinese Han individuals, after adjusting for conventional risk factors, 192R allele carriers had a significantly higher risk of CAD than other allele carriers . The mechanism is clear: the diminished ability of the RR variant genotype of PON1 to blunt LDL oxidation allows oxidized LDL to accumulate in artery walls.

Interestingly, the cardiovascular risk associated with the R allele shows ethnic variation⁵⁵ ethnic variation
Genetic risk can vary across populations due to differences in genetic background and environmental exposures.

In Asian populations, the 192R allele was a susceptible factor for type 2 diabetes, but represented a protective factor in the European population (OR = 0.66, 95% CI = 0.45-0.98) under a heterozygous genetic model . This may reflect different patterns of oxidative stress, diet, or gene-gene interactions across populations.

For organophosphate exposure, the evidence is also compelling.

A meta-analysis of nine studies with 1,042 patients showed that the PON1 192Q polymorphism increases the risk of organophosphate toxicity , with significant associations among Caucasian populations .

In Colombian coffee harvesters, the 192Q genotype was associated with hypertension , potentially reflecting both cardiovascular vulnerability and cumulative pesticide exposure effects.

Practical Implications

Your genotype shapes how your body handles two distinct challenges: protecting your arteries from oxidative damage and clearing environmental toxins. QQ individuals have superior antioxidant protection but are more vulnerable to organophosphate toxicity. RR individuals have the opposite profile—better pesticide clearance but reduced cardiovascular protection. Heterozygotes (QR) fall somewhere in between.

For cardiovascular health, tomato juice consumption reduced LDL oxidation and improved antioxidant status in R-allele carriers, but not in the QQ genotype group , suggesting dietary antioxidants may compensate for the R variant's reduced intrinsic antioxidant capacity. Polyphenol-rich foods (berries, green tea, dark chocolate, olive oil) provide similar oxidized LDL protection.

If you have occupational or recreational exposure to organophosphate pesticides (agricultural work, home gardening with conventional pesticides), your Q192R genotype affects your vulnerability. QQ individuals should be especially cautious about pesticide exposure, using protective equipment and favoring organic produce when practical.

Interactions

The Q192R polymorphism interacts with PON1 L55M (rs854560)⁶⁶ PON1 L55M (rs854560)
Another PON1 variant affecting enzyme expression levels; the M allele is associated with lower PON1 concentrations in the same gene.

The 55M homozygotes have over 50% less activity toward paraoxon compared to the LL and LM genotypes regardless of the 192 genotype, and the 55 polymorphism accounts for 16% of the variation in PON1 activity . The combination of Q192R with unfavorable L55M genotypes compounds cardiovascular risk and pesticide sensitivity.

In rheumatoid arthritis patients, the TLQ haplotype (combining promoter, L55M, and Q192R variants) was associated with low PON1 activity (OR = 2.29) and low PON1 protein levels (OR = 1.65) , demonstrating how multiple PON1 variants can synergistically impair enzyme function.

Inside every cell, a set of enzymes quietly edits transfer RNA — the molecular adaptors that read genetic code and build proteins. CDKAL1 encodes one of these editors: a methylthiotransferase¹¹ methylthiotransferase
An enzyme that adds a methylthio (-SCH₃) chemical group to a specific adenosine residue (ms²t⁶A₃₇) in tRNA, essential for accurate translation of codons beginning with adenosine that modifies tRNA at position 37, adjacent to the anticodon loop. This modification ensures the ribosome reads ANN codons faithfully — without it, mistranslation errors accumulate, affecting proteins whose synthesis depends on those codons. rs6908425 is an intronic variant in CDKAL1 whose C allele has been reproducibly associated with Crohn's disease risk across multiple large GWAS studies.

The Mechanism

rs6908425 sits in an intron of CDKAL1 at chromosome 6, position 20,728,500 (GRCh38). As an intronic variant it does not change the protein sequence directly, but it likely acts as a regulatory tag²² regulatory tag
Intronic variants can alter splicing efficiency, branch point usage, or intronic regulatory elements that control transcription. rs6908425 is in strong linkage disequilibrium with functional variants in CDKAL1 that affect gene expression levels.

Quaranta et al. (2009)³³ Quaranta et al. (2009)
Quaranta M et al. Differential contribution of CDKAL1 variants to psoriasis, Crohn's disease and type II diabetes. Genes & Immunity, 2009 made a critical observation: CDKAL1 transcripts are virtually absent from skin keratinocytes but are abundantly expressed in immune cells — particularly CD4+ T lymphocytes and CD19+ B lymphocytes — and are markedly downregulated when those cells receive proliferating signals. This expression pattern explains why CDKAL1 variants influence immune-mediated diseases: the gene's tRNA modification activity is most important in actively translating immune cells. Impaired tRNA editing in lymphocytes may reduce the fidelity of cytokine and receptor protein synthesis, contributing to dysregulated immune activation.

The Evidence

Barrett et al. (2008)⁴⁴ Barrett et al. (2008)
Barrett JC et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nature Genetics, 2008 identified rs6908425-C as a Crohn's disease susceptibility allele with OR 1.21 (P=9×10⁻¹⁰) in a large multi-stage GWAS. This was replicated by Liu et al. (2015)⁵⁵ Liu et al. (2015) in a larger IBD meta-analysis (OR 1.11, P=5×10⁻¹²), and by Franke et al. (2010)⁶⁶ Franke et al. (2010) (OR 1.17, P=1×10⁻⁸). The same GWAS data showed a weaker ulcerative colitis association (OR 1.07, P=4×10⁻⁶), indicating the primary signal is in Crohn's disease specifically.

Quaranta et al. (2009)⁷⁷ Quaranta et al. (2009)
Quaranta M et al. Differential contribution of CDKAL1 variants to psoriasis, Crohn's disease and type II diabetes. Genes & Immunity, 2009 demonstrated that CDKAL1's risk allele for Crohn's disease and psoriasis is independent of the CDKAL1 T2D association: the same genomic region harbors distinct alleles driving disease-specific risk through different cell types. For psoriasis, the rs6908425 association reached OR 1.26–1.28 (combined P=4×10⁻⁶ across 2,579 cases and 4,306 controls).

Umeno et al. (2011)⁸⁸ Umeno et al. (2011)
Umeno J et al. Meta-analysis of published studies identified eight additional common susceptibility loci for Crohn's disease and ulcerative colitis. Inflammatory Bowel Disease, 2011 confirmed CDKAL1 among eight loci with modest effect sizes (OR 1.05–1.22) shared across IBD phenotypes. Evidence is strong: consistent replication across independent European and international cohorts with cumulative sample sizes in the tens of thousands.

The variant also shows a modest negative association with body mass index (beta −0.0095 per C allele, P=2×10⁻⁹) in a 2022 GWAS, consistent with CDKAL1's broader metabolic role in pancreatic beta cells and tRNA-mediated translational fidelity.

Practical Actions

Carrying one or two copies of the C allele does not guarantee Crohn's disease — it modestly shifts population-level risk. The C allele is common (~79% globally), meaning most people carry it. The actionable value for CC homozygotes lies in earlier vigilance for gastrointestinal symptoms, understanding of specific dietary patterns that support the intestinal mucosal barrier in genetically susceptible individuals, and awareness that anti-TNF biologic therapy is particularly relevant to this genetic risk pathway.

Crohn's disease in CDKAL1 C-allele carriers arises from a dysregulated mucosal immune response — supporting gut barrier integrity through targeted dietary and supplement strategies is genotype-relevant advice for CC individuals with gastrointestinal symptoms.

Interactions

CDKAL1 rs6908425 is part of a broader inflammatory genome. Its Crohn's disease signal is independent from the CDKAL1 T2D risk variants, demonstrating allelic heterogeneity at this locus. Individuals carrying both CDKAL1 risk alleles and IL23R risk alleles (rs11209026, rs2201841) have compounding risk for inflammatory bowel disease through the IL-23/Th17 pathway that governs mucosal immune responses in the gut. IBD risk is highly polygenic, and CDKAL1 C-allele status should be interpreted alongside ATG16L1, NOD2, and IL23R genotypes when available.